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Abstract
Introduction: Pharyngo-laryngeal tumors classiﬁ  ed as T3-4, N0-3, M0, are conventionally treated by mutilating surgery 
(total (pharyngo)-laryngectomy). Neo-adjuvant chemotherapy with 5-FU/platinum salt can be proposed in an attempt to 
preserve the larynx. The level of the response to chemotherapy ranges from 36 to 54% of cases. Thus, a large number of 
patients receive chemotherapy that is ineffective and not free from adverse effects. Three main enzymes are involved in the 
metabolism of 5-FU: thymidylate synthase (TS), thymidylate phosphorylase (TP) and dihydropyrimidine dehydrogenase 
(DPD). Several studies suggest that a high level of expression of these three genes correlates with a poor clinical response 
to 5-FU. The main purpose of our study was to look for a correlation between the levels of expression of the genes for 
sensitivity to 5-FU (TS, TP, DPD) within the tumor and the clinical response observed after three courses of chemotherapy 
combining 5-FU/platinum salt in patients presenting with advanced cancer of the pharyngo-larynx.
Methods: This was a prospective genetic study that had required approval from the Ethics Committee. The main assessment 
criterion was based on the assessment of the clinical response by an ENT panendoscopy and a cervical CT scan, after three 
courses of chemotherapy. The expression of the genes was determined by quantitative RT-PCR, using total RNA extracted 
from tumor biopsies taken during the initial panendoscopy.
Results: The means calculated, in our study, for the three genes of interest (TS, TP, DPD) were lower in the responder group 
than those in the non-responder group.
Discussion: Our preliminary ﬁ  ndings reveal trends that conﬁ  rm the hypothesis that the lower the level of expression of the 
sensitivity genes, the better the clinical response to chemotherapy. They now form part of a larger study that is currently in 
progress.
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Introduction
Over the past 20 years, advances in the treatment of pharyngo-laryngeal epidermoid carcinomas have 
made it possible to reduce the functional impact on swallowing, breathing and speaking. Cancers classi-
ﬁ  ed as T3 or T4, N0-3, and M0 are conventionally treated by total (pharyngo)-laryngectomy (T(P)L). For 
the past few years, it has been possible to propose combined chemotherapy with 5-ﬂ  uoro-uracyl (5-FU) 
plus a platinum salt (Cisplatin or Paraplatin), thus preserving the larynx. This chemotherapy produces a 
regression of the lesions in 36 to 54% of cases (1, 2). 5-FU is an anti-metabolite with a chemical structure 
analogous to that of pyrimidine bases. Three essential enzymes are implicated in its metabolism: thymi-
dylate synthase (TS), thymidylate phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD). TS 
is an essential enzyme in the synthesis of DNA, and when it is blocked by a metabolite of 5-FU (5-FdUMP) 
this results in the inhibition of the synthesis of DNA. TP, an enzyme involved in the anabolism of 5-FU, 
is also involved in tumor neoangiogenesis (3). DPD is an enzyme involved in the catabolism of 
5-FU. Patients with low DPD activity are unable to activate 5-FU effectively, which results in the accu-
mulation of toxic active metabolites. The mechanisms of resistance to 5-FU may either be present prior 28
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to the treatment or be acquired during treatment. 
Several possible mechanisms have been proposed, 
but their real clinical involvement remains to be 
demonstrated. Studies of colo-rectal and gastric 
adenocarcinomas have demonstrated that the 
expression of the genes depends on the tumors 
involved, and there is a correlation between the 
expression of the TS, TP, and DPD genes and their 
translation into proteins for a given tumor (4, 5). 
According to several studies, the levels of expres-
sion of mRNA of these three enzymes in colon 
tumors are indicators that predict the sensitivity to 
5-FU (6–8), and their over-expression within the 
tumor is one of the mechanisms of resistance to 
5-FU (9). There have been few studies of ENT 
cancers, and their ﬁ  ndings are contradictory. A study 
of cancers at several sites in the head and neck 
highlights the importance of determining the expres-
sion of TS in order to identify the patients who could 
beneﬁ  t from 5-FU treatment (10), something not 
conﬁ  rmed by two more recent studies (11, 12). In 
the case of DPD, the study by Kawasaki et al. (11) 
demonstrates a statistically signiﬁ  cant relationship 
between the expression of DPD in the tumor and 
the clinical response to 5-FU, a relationship not 
found in the study by Etienne et al. (12). No study 
of TP in ENT cancers has been published.
The reverse transcription and quantitative real-
time polymerase chain reaction (RT-PCR) tech-
niques make it possible to determine the expression 
of various genes using small tumor fragments.
The aim of our study was to look for a relation-
ship between the levels of expression within the 
tumor of the genes for 5-FU sensitivity (TS, TP, 
DPD) and the clinical response observed after three 
courses of chemotherapy using a combination of 
5-FU/platinum salt, in T3-4, N0-3, M0 pharyngo-
laryngeal cancers. The clinical aim was to be able 
to identify patients who would not respond to the 
chemotherapy, in order to propose radical surgery 
from the outset.
Materials and Methods
Materials
Type of study
This was a prospective, single-center study with 
no direct individual beneﬁ  t, carried out over a 
period of 6 months. The protocol of the study has 
been submitted to the Ethics Committee.
Patient inclusion criteria
The patients presented with an operable epidermoid 
carcinoma of the larynx or hypopharynx, classiﬁ  ed 
as T3 or T4, N0-3, M0 (TNM classiﬁ  cation) for 
which it had been decided there was a therapeutic 
indication for neoadjuvant chemotherapy, consist-
ing of three courses of a combination of 5-FU/
platinum salt. Each course lasted 5 days. The inter-
val between two successive courses was 21 days 
(D1= DJ21). The doses administered during each 
course were 100 mg/m
2 of Cisplatin on D1, and a 
continuous infusion of 1000 mg/m
2/d of 5-FU from 
D1 to D5. The patients’ general condition was 
compatible with the introduction of chemotherapy 
(WHO Performance Status (PS) Scale  2 or 
Karnofsky Index  60%). The patients were over 
18 years of age. They had been informed about the 
study, and had signed an informed consent form.
Biological material
Tumor biopsies were taken during the initial pan-
endoscopy. The pathologist placed them in cryo-
tubes and then froze then at –80 °C in the tumor 
archive.
Methods
Initial TNM classiﬁ  cation
This was carried out after a panendoscopy and a 
cervical tomodensitometry.
Experimental protocol
The determination of the expression of the genes 
for sensitivity to 5-FU (TS, TP, DPD) within the 
tumor was carried out in three successive steps: 
extraction of the total RNA, reverse transcription 
and real-time polymerase chain reaction 
(PCR).
RNA extraction
This was carried out using the principle of the 
RNeasy kit, which is based on selective binding of 
RNA to silica gel in columns. Frozen tumor biopsy 
samples (30 mg) were ground in liquid nitrogen 
with steel ball bearings, using a tissue mill (Mixer 
Mill MM 300, Qiagen). The ground tissue was then 
subjected to lysis in a guanidine isothiocyanate 
buffer, to denature the proteins and inactivate the 
RNases. The lysate obtained was mixed with etha-
nol, which produced selective binding of the RNA 29
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to a membrane containing silica gel. In order to 
ensure the purity of the RNA, an additional diges-
tion step using DNase I was included in the proto-
col. The bound RNA was then eluted using 
«RNase-free» water. The quality of the RNA was 
systematically checked by migration on agar gel 
(electrophoresis), and the quantity obtained was 
determined by spectrophotometric assay. Any RNA 
that appeared to be damaged during the electropho-
resis was routinely excluded from the analysis.
Reverse transcription
This is used to transcribe RNA into complementary 
DNA (cDNA) using inverse transcriptase from an 
oligo-d(T)15, which has the property of forming a 
hybrid with the poly-A tail of eucaryotic mRNA. 
The enzyme used in our study was AMV reverse 
transcriptase (Avian-Myeloblastosis-Virus). Each 
reverse transcription was carried out using 0.5 µg 
of mRNA. The mRNA was exposed to 20 U of 
AMV reverse transcriptase, 10 mM of dNTP, 
1.6 µg of oligo d(T)15 primers and of 40 U of 
RNase inhibitor, according to the following 
sequences: 10 minutes at 25 °C, 1 hour at 55 °C 
and 5 minutes at 94 °C. For each sample, an 
RT-negative (RT-) and RNA-negative (RNA-) 
control was carried out to conﬁ  rm the absence of 
DNA contamination in the RNA extract, and the 
absence of contamination of the mix used for the 
RT reaction respectively.
Real-time polymerase chain reaction (PCR)
This method is used to monitor the ampliﬁ  cation 
of the candidate gene as the reaction progresses. It 
uses a fluorochrome, SYBR GreenI, which is 
incorporated in a small channel in double-stranded 
DNA. Speciﬁ  c software for the Light Cycler was 
used to measure the total ﬂ  uorescence, which is 
proportional to the number of molecules of the 
ampliﬁ  ed gene. In addition, the presence of SYBR 
GreenI in the reaction medium makes it possible 
to plot the fusion curves for the double-stranded 
DNA, and thus to conﬁ  rm the speciﬁ  city of the 
ampliﬁ  cation characterized by the Tm (fusion or 
denaturing temperature of the DNA fragment). 
A pair of speciﬁ  c primers was used for each gene 
of interest (Table 1). The dilution range was pre-
pared from external standards consisting of RNA 
extracts from a colo-rectal cancer cell line (WiDr). 
The RNA obtained in this way was then retro-
transcribed into cDNA, before being ampliﬁ  ed 
using the Light Cycler under the same conditions 
as those used for the cDNA from the samples in 
the tumor archive. The standards were used to 
produce a range of dilutions of cDNA. Each tran-
scription product was ampliﬁ  ed without diluting 
(pure), and after diluting tenfold (d10), one-hun-
dred fold (d100) and one thousand fold (d1000). 
The higher the concentration of the cDNA of the 
gene of interest in the sample, the earlier the ampli-
ﬁ  cation from the speciﬁ  c primers started. This 
made it possible to plot a regression line to deter-
mine the initial concentration of the mRNA of the 
gene of interest. In order to conﬁ  rm the values 
obtained, each sample was measured in duplicate 
and twice for each gene. The mean of the four 
values obtained was calculated. Only results within 
the standard range were accepted. Contamination 
was detected as the presence of DNA in the blank 
and in the RT- and RNA-controls. A reference gene 
(glucose-6-phosphate dehydrogenase (G6PDH)) 
was required for the purpose of quantiﬁ  cation. Its 
role was to ensure that there were no measurement 
Gene Primers Fragment ampliﬁ  ed (bp)
G6PDH Sense: 5´-TggAgAATgAgAggTggg ATg-3´
Antisense: 5´-gAgCTTCACgTTCTTgTATCTgT-3´
269 bp
TS Sense: 5´-AgCCTgAgAgATgAATTCCC-3´
Antisense: 5´-CTCTggTggAgAATCCCAgg-3´
184 bp
TP Sense: 5´-CAgATCggggCCATgCTgAT-3´
Antisense: 5´-ATCCAAggTgCCTCCTgTgTg-3’
261 bp
DPD Sense: 5´-gATTCTggCTACCAggCTATACA-3´
Antisense: 5´-CCggATTCACAgATAAgggTACg-3´
178 bp
Table 1. Speciﬁ  c primers used for PCR (bp: base pair).30
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errors due to any pipetting errors, discrepancies in 
the assay of the matrix or the RT reactions.
The ratio of the concentration of mRNA of the 
gene of interest (TS, TP, DPD) over the concentra-
tion of the mRNA of the reference gene was used 
to determine the level of expression of the mRNA 
of the gene of interest.
Main assessment criterion
The main assessment criterion was based on the 
clinical response after three courses of chemo-
therapy. This was assessed by a panendoscopy and 
a cervical tomodensitometry, during the 2 weeks 
following the third course of chemotherapy. The 
two panendoscopies (initial and after the 3rd 
course) were carried out by the same operator. The 
clinical response was determined objectively, 
according to the WHO criteria (Table 2), and the 
patients were then divided into two groups: the 
responder group (R), consisting of the patients 
displaying a complete response (RC) or a partial 
response (RP), and the non-responder group (NR), 
consisting of the patients with progressive (PD) or 
stable (SD) disease.
Statistical analysis
The statistical analysis consisted of calculating the 
means and standard deviations of the degree of 
expression of the mRNA of the genes of interest, 
in the responder (R) and non-responder (NR) 
groups.
Results
All the patients included were men (Table 3). Their 
group mean age was 58.5 years. Five patients 
presented with a lesion of the larynx, and ﬁ  ve with 
one of the hypopharynx. With regard to their histol-
ogy, four patients presented with a clearly differ-
entiated epidermoid carcinoma and six patients 
with a carcinoma that was only moderately or 
slightly differentiated. The patients were all given 
three courses of chemotherapy with 5-FU plus a 
platinum salt, apart from three patients who dis-
played disease progression during chemotherapy 
(numbers 2, 7 and 8). One of these three patients 
showed disease progression at the end of the third 
course of chemotherapy that led to his being clas-
siﬁ  ed as inoperable, and so a fourth course of 
chemotherapy was administered followed by radio-
therapy. The second patient displayed disease 
progression, making it necessary to carry out an 
emergency tracheotomy, followed by surgery (total 
pharyngo-laryngectomy), two weeks after the end 
of the ﬁ  rst course of chemotherapy. The third 
patient displayed secondary lesions on his lungs 
after C2, which led to the continuation of the 
courses of chemotherapy combined with radio-
therapy. The clinical outcome consisted of 5 partial 
responses, one complete response, one case in 
which the disease remained stable and three cases 
of disease progression (Table 4). We saw only one 
case in which the organ was preserved after a 
complete response. All the responder patients were 
classiﬁ  ed as T3. The levels of TS, TP and DPD 
mRNA within the tumor were measured in each 
patient. The lowest level of expression of TS was 
3.34 ARU (arbitrary relative units), and the highest 
34.45 ARU (Fig. 1). The mean values obtained in 
the responder (R) and non-responder (NR) groups 
were 5.61 ARU [3.34; 9.55] and 12.52 ARU [4.33; 
34.45] respectively. The standard deviations for 
the R and NR groups were 2.37 and 14.70 respec-
tively. The lowest level of expression of TP was 
12.93 ARU, and the highest 245.15 ARU (Fig. 2). 
The mean values obtained in the R and NR groups 
were 66.31 ARU [12.93; 214.79] and 96.27 ARU 
[15.09; 245.15] respectively. The standard devia-
tions for the R and NR groups were 73.83 and 
102.27 respectively. The lowest level of expression 
of DPD was 1.35 ARU, and the highest 77.2 ARU 
(Fig. 3). The mean values obtained in the R and 
NR groups were 25.04 ARU [1.35; 77.2] and 30.68 
Table 2. WHO criteria for the response to chemotherapy.
Response Deﬁ  nition
Complete response (CR)  Complete disappearance of the tumor visible or palpable
Partial response (RP)  Reduction in the size of the tumor by at least 50%
Stable disease (SD)  No response or progression of the tumor
Progressive disease (PD)  Increase by more than 25% in the size of the tumor31
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ARU [1.36; 57.33] respectively. The standard 
deviations in the R and NR groups were 28.30 and 
22.90 respectively.
Discussion
Our study was intended to look for a correlation 
between the levels of expression of the genes for 
sensitivity to 5-FU (TS, TP, DPD) within the tumor 
and the clinical response to the chemotherapy, 
consisting of a combination of 5-FU plus a plati-
num salt, in patients with a cancer of pharyngolar-
ynx classiﬁ  ed as T3-4, N0-3, M0. These preliminary 
ﬁ  ndings are part of a wider study currently in 
progress. Although we do not provide any signiﬁ  -
cant results, there does seem to be a trend that 
supports the initial hypothesis that the higher the 
levels of expression of the mRNA of TS, TP, DPD 
within the tumor, the lower the clinical response 
to chemotherapy. The mean values obtained in our 
study for the 3 genes of interest (TS, TP, DPD) 
were lower in the R group than in the NR group. 
According to some studies, these 3 genes for sen-
sitivity to 5-FU are independent factors (9, 11), 
which could explain why some patients were clas-
siﬁ  ed as responders even though they displayed a 
high level of expression of one of these genes.
The literature includes only 4 studies concern-
ing the genes for sensitivity to 5-FU in ENT can-
cers (10–13). Three of these 4 studies were 
prospective studies, and one was a retrospective 
study. They included far greater numbers of 
patients: 109 (10), 62 (11), 82 (12) and 86 (13) 
respectively, but were carried out over several 
years. In our study, we chose to include only 
patients presenting with an epidermoid carcinoma 
of the pharyngolarynx, in contrast to the other 
studies (10, 12, 13), which had included a wide 
variety of cancers of the head and neck. Kawasaki 
et al. (11) included only epidermoid carcinomas of 
the buccal cavity. Furthermore, these studies 
included all tumor stages (T1-4), whereas we only 
included advanced stages of pharyngolaryngeal 
cancer (T3-4). Our study had a speciﬁ  c clinical 
objective, that of being able to select patients likely 
to respond to neo-adjuvant chemotherapy, with the 
aim of preserving the larynx. We did not include 
any patients classiﬁ  ed as inoperable and who were 
receiving treatment with a combination of chemo-
therapy (5-FU/platinum salt)-radiotherapy. This 
was in order to enable us to differentiate between 
the effects of chemotherapy and radiotherapy on 
the clinical response, and so avoid bias in the 
analysis of the results, unlike the study of Etienne 
et al. (12). The chemotherapy protocol used in our 
Table 3. Description of the population.
Identi-   Sex (a)  Age   Site (b)  Histology (c)  TNM  No.   Outcome  Treatment
ﬁ  cation    (years)        courses  after C3 (d)  after C3 (e)
number
1  M  49  Larynx G  1  T3 N2a M0  3  PR  TPL + RX
2  M  75  Epiglottis  2  T3 N3 M0  4  PD  C4 + RX
3  M  44  R Larynx   1  T3 N0 M0  3  PR  TPL + RX
4  M  65  R Piriform Sinus  2  T3 N0 M0  3  RC  RX
5  M  51  L Piriform Sinus  1  T3 N2a M0  3  PR  TPL + RX
6  M  76  L Larynx  2  T4 N0 M0  3  SD  RX
7  M  60  R Piriform Sinus  2  T4 N3 M0  1  PD  TPL + RX
8  M  49  R Larynx   1  T3 N0 M0  3  PR  TPL + RX
9  M  75  R Piriform Sinus  2  T3 N2b M0  6  PD  C6 + RX
10  M  41  L Piriform Sinus  2  T3 N3 M0  3  PR  TPL + RX
(a): sex; M: male. (b): tumor site; R: right; L: left. (c): Histology; 1: clearly-differentiated epidermoid carcinoma; 2: moderately or slightly 
differentiated epidermoid carcinoma. (d): outcome after C3; PR: partial response; CR: complete response; PD: progressive disease; 
SD: stable disease. (e): Treatment after C3; TPL: total pharyngo-laryngectomy; RX: radiotherapy; Cx: xth course of chemotherapy.
Table 4. Distribution of the patients on the basis of their 
TNM classification and clinical response to neo-
adjuvant chemotherapy.
 PR  CR  SD  PD  Total
T3 N0 M0  2  1  0  0  3
T3 N2a M0  2  0  0  0  2
T3 N2b M0  1  0  0  1  2
T3 N3 M0  0  0  0  1  1
T4 N0 M0  0  0  1  0  1
T4 N3 M0  0  0  0  1  1
Total 5  1  1  3  1032
Aubry et al
Clinical Medicine: Oncology 2008:2
study was the same as that used by Etienne et al. 
(12, 13) but different from that of Johnston et al. 
(10). Consequently, our work is difﬁ  cult to com-
pare to that of other authors. We worked on tumor 
biopsies taken during the initial panendoscopy, 
under visual control, in the same way as Etienne 
et al. (12). This technique has its limitations, since 
the sample may have been taken from a heteroge-
neous fragment of tumor or at the edge of the 
tumor, and so contain healthy cells. In order to 
improve the reliability of the sample, it would be 
useful to use the laser microdissection method, 
which makes it possible to isolate tumor cells 
within a heterogeneous tissue.
We studied the level of DPD mRNA in the 
tumor. Some studies stress the value of determin-
ing this level not only in the tumor, but also in the 
healthy tissue around the tumor (11, 12). According 
to these publications, it is only the ratio (of the 
expression of DPD in the tumor to that in the non-
tumor tissue) that correlates to the response to 
chemotherapy. In our study, no healthy tissue could 
be taken for ethical reasons.
We chose to measure the levels of expression of 
the genes for sensitivity to 5-FU, using the quantita-
tive RT-PCR technique. This is a method that is 
suitable for use with small samples, such as our 
tumor biopsies. It is also quantitative and readily 
reproducible, unlike immunohistochemistry and 
enzymology methods. Immunohistochemistry is a 
qualitative technique that involves at least two dif-
ferent observers (10, 11). Enzymology requires larger 
tumor samples, and it is also more fastidious and less 
reproducible than RT-PCR (12, 13). However, these 
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two techniques directly involve the protein produced 
by the genes for sensitivity to 5-FU, whereas the 
RT-PCR determination measures the level of mRNA. 
This does not seem to be a drawback since it has 
been shown that in colorectal and gastric tumors the 
level of mRNA is closely correlated with the level 
of protein produced (4, 5).
The calibration range used in our study was 
prepared from a line of colo-rectal cancer cells 
(WiDr). Although they are not of the same histo-
logical type as epidermoid carcinomas of the 
pharyngolarynx, we used them as the reference. 
The values obtained were in fact expressed in an 
arbitrary relative unit (ARU), so that only a com-
parison of the different values was meaningful, the 
long-term aim being to establish an expression 
value that would distinguish between responders 
and non responders.
Our main assessment criterion was based on the 
clinical assessment after C3 by a panendoscopy 
and a cervical CT scan. This was the same as the 
criterion used by Etienne et al. (12, 13). The pan-
endoscopy was not ideal since it was partly subjec-
tive. In order to increase its reliability, the lesion 
was tattooed during the initial panendoscopy and 
the 2 panendoscopies (initial and after C3) were 
carried out by the same operator.
We think that other factors may also be involved 
in the response to chemotherapy, including other 
genes for sensitivity to 5-FU, the associated plati-
num salt, interindividual variability of the 
pharmacokinetics of 5-FU and the patient’s general 
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condition. Orotate phosphoribosyl transferase 
(OPRT) is an enzyme corresponding to the alterna-
tive pathway to that of TS for the anabolism of 
5-FU. The study of Ichikawa et al. carried out on 
metastatic colo-rectal cancers, concludes that the 
level of expression of mRNA of OPRT could be 
an index of the efﬁ  cacy of the chemotherapy (14). 
All our patients were treated with a combination 
of 5-FU/platinum salt. The platinum salt probably 
contributes to the response to chemotherapy, even 
though it is accepted that 5-FU plays the predom-
inant role in this combination (15, 16). Excision 
Repair Cross Complementing 1 (ERCC1), is an 
enzyme involved in the excision-repair of the 
anomalies created by the insertion of platinum 
compounds into the DNA helix. According to the 
study of Metzger et al. (17), carried out on gastric 
cancers, the expression of ERCC1 and of TS in the 
tumor are two independent variables, correlated 
with the clinical response to chemotherapy com-
bining 5-FU and cisplatin. Furthermore, dosage 
adaptation of 5-FU seems to be interesting due to 
a high degree of interindividual variability in the 
clearance of the drug (18). An essential factor in 
the variability of the pharmacokinetics of 5-FU is 
the activity of DPD. This activity has been shown 
to display a circadian rhythm, which is responsible 
for an increase in the plasma concentrations of 
5-FU during the night, during continuous infusions 
(19). Finally the patient’s general status probably 
plays a non-negligible role in the response to che-
motherapy, however, we think that its role in our 
study was limited, since all the patients included 
displayed a general condition compatible with 
beginning chemotherapy (WHO Performance 
Status ≤ 2 or Karnofsky index  60%).
Conclusion
This study is intended to contribute to establishing 
the pharmacogenetics, which in turn is intended to 
establish the individual proﬁ  le of the response to 
chemotherapy. The preliminary ﬁ  ndings of this pro-
spective study are interesting and encourage us to 
continue by extending it to other sensitivity genes, 
in particular OPRT and ERCC1, and through the use 
of the multiple microdisplay of gene expression.
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